(NASDAQ: SRPT) Sarepta Therapeutics's forecast annual revenue growth rate of 13.21% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Sarepta Therapeutics's revenue in 2025 is $2,233,371,000.On average, 10 Wall Street analysts forecast SRPT's revenue for 2025 to be $251,483,455,834, with the lowest SRPT revenue forecast at $231,502,457,627, and the highest SRPT revenue forecast at $268,777,854,817. On average, 10 Wall Street analysts forecast SRPT's revenue for 2026 to be $280,791,435,763, with the lowest SRPT revenue forecast at $239,364,521,910, and the highest SRPT revenue forecast at $351,930,051,592.
In 2027, SRPT is forecast to generate $320,831,857,248 in revenue, with the lowest revenue forecast at $274,655,214,439 and the highest revenue forecast at $373,973,589,870.